The USFDA conducted an inspection from 15 to 19 July 2024, and has been classified as Voluntary Action Indicated (VAI).
Zydus Lifesciences is a discovery-driven, global life sciences company that discovers, develops, manufactures, and markets a broad range of healthcare therapies.
The pharma company’s consolidated net profit surged 30.64% to Rs 1,419.9 crore in Q1 FY25 as compared to Rs 1,086.9 crore posted in Q1 FY24. Revenue from operations jumped 20.77% year on year (YoY) to Rs 6,207.5 crore in the quarter ended 30 June 2024.
Shares of Zydus Lifesciences rose 0.12% to currently trade at Rs 1,069.60 on the BSE.